Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427397 | 0.81 | CTSK (0.42) | MAPTLMNAKDM4EMAPK1ALDH1A1 | |
| SCHEMBL3399391 | 0.81 | ALDH1A1 (0.47) | MAPTLMNAKDM4EHTTMAPK1 | |
| SCHEMBL3405186 | 0.80 | KMT2A (0.41) | MAPTLMNAKDM4EHTTMAPK1 | |
| SCHEMBL3403998 | 0.79 | ALDH1A1 (0.44) | MAPTLMNAKDM4EHTTMAPK1 | |
| SCHEMBL3401385 | 0.78 | ALDH1A1 (0.42) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL3425360 | 0.78 | ALDH1A1 (0.42) | MAPTLMNAKDM4EHTTMAPK1 | |
| SCHEMBL3407918 | 0.77 | ACKR3 (0.41) | MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL3402400 | 0.77 | ALDH1A1 (0.50) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL3402065 | 0.76 | ALDH1A1 (0.42) | MAPTLMNAKDM4EHTTMAPK1 | |
| SCHEMBL6949324 | 0.74 | KDM4E (0.52) | MAPTLMNAKDM4EGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | MAPT 2266/4885LMNA 4511/4885KDM4E 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.